Similar articles

• Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.

  Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Mueck AO, et al. Menopause. 2007 Nov-Dec;14(6):978-84. doi: 10.1097/gme.0b013e318054e2e7. Menopause. 2007. PMID: 17595593 Clinical Trial.
• Is there a place for postmenopausal hormone therapy use in women with lupus?

  Gompel A, Piette JC. Gompel A, et al. Panminerva Med. 2008 Sep;50(3):247-54. Panminerva Med. 2008. PMID: 18927529 Review.
• The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?

  Shulman LP. Shulman LP. J Fam Pract. 2004 Jul;Suppl:S13-7. J Fam Pract. 2004. PMID: 15251108 Review. No abstract available.
• Association of oral but not transdermal estrogen therapy with enhanced platelet reactivity in a subset of postmenopausal women.

  Flaumenhaft R, Nachtigall M, Lowenstein J, Nachtigall L, Nachtigall R, Nachtigall L. Flaumenhaft R, et al. Menopause. 2009 Mar-Apr;16(2):407-12. doi: 10.1097/gme.0b013e3181833886. Menopause. 2009. PMID: 18989235
• Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women.

  Olié V, Canonico M, Scarabin PY. Olié V, et al. Curr Opin Hematol. 2010 Sep;17(5):457-63. doi: 10.1097/MOH.0b013e32833c07bc. Curr Opin Hematol. 2010. PMID: 20601871 Review.